Identification of a Novel Prognostic Signature Based on N-Linked Glycosylation and Its Correlation with Immunotherapy Response in Hepatocellular Carcinoma

References

• Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534–1545. doi:10.1002/ijc.30211
   PubMed Web of Science ®Google Scholar
• Killock D. Immunotherapy: nivolumab keeps HCC in check and opens avenues for checkmate. Nat Rev Clin Oncol. 2017;14(7):392. doi:10.1038/nrclinonc.2017.70
   PubMed Web of Science ®Google Scholar
• Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol. 2011;21(5):576–582. doi:10.1016/j.sbi.2011.08.005
   PubMed Web of Science ®Google Scholar
• Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem. 2004;73(1):1019–1049. doi:10.1146/annurev.biochem.73.011303.073752
   PubMedGoogle Scholar
• Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5(7):526–542. doi:10.1038/nrc1649
   PubMed Web of Science ®Google Scholar
• Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002;99(16):10231–10233. doi:10.1073/pnas.172380699
   PubMed Web of Science ®Google Scholar
• Chandler KB, Costello CE, Rahimi N. Glycosylation in the tumor microenvironment: implications for tumor angiogenesis and metastasis. Cells. 2019;8(6):544.
   PubMed Web of Science ®Google Scholar
• Laubli H, Borsig L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 2019;10:2120. doi:10.3389/fimmu.2019.02120
   PubMed Web of Science ®Google Scholar
• Li CW, Lim S-O, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201 e10. doi:10.1016/j.ccell.2018.01.009
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–555. doi:10.1038/nrc3982
   PubMed Web of Science ®Google Scholar
• Li CW, Lim S-O, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7(1):12632. doi:10.1038/ncomms12632
   PubMed Web of Science ®Google Scholar
• Cherepanova N, Shrimal S, Gilmore R. N-linked glycosylation and homeostasis of the endoplasmic reticulum. Curr Opin Cell Biol. 2016;41:57–65. doi:10.1016/j.ceb.2016.03.021
   PubMed Web of Science ®Google Scholar
• Verheijen J, Tahata S, Kozicz T, et al. Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020;22(2):268–279. doi:10.1038/s41436-019-0647-2
   PubMed Web of Science ®Google Scholar
• Breitling J, Aebi M. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harb Perspect Biol. 2013;5(8):a013359. doi:10.1101/cshperspect.a013359
   PubMed Web of Science ®Google Scholar
• Sha S, Agarabi C, Brorson K, et al. N-glycosylation design and control of therapeutic monoclonal antibodies. Trends Biotechnol. 2016;34(10):835–846. doi:10.1016/j.tibtech.2016.02.013
   PubMed Web of Science ®Google Scholar
• Morelle W, Potelle S, Witters P, et al. Galactose supplementation in patients with TMEM165-CDG rescues the glycosylation defects. J Clin Endocrinol Metab. 2017;102(4):1375–1386. doi:10.1210/jc.2016-3443
   PubMed Web of Science ®Google Scholar
• Sparks SE, Krasnewich DM. Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview, in GeneReviews((R)). Adam MP Editors. Seattle (WA); 1993.
   Google Scholar
• Dalziel M, Crispin M, Scanlan CN, et al. Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014;343(6166):1235681. doi:10.1126/science.1235681
   PubMed Web of Science ®Google Scholar
• Schjoldager KT, Narimatsu Y, Joshi HJ, et al. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21(12):729–749. doi:10.1038/s41580-020-00294-x
   PubMed Web of Science ®Google Scholar
• Hou HL, Ge C, Sun H, et al. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD 44s and the ERK 1/2 pathway. Cancer Sci. 2018;109(4):1088–1100. doi:10.1111/cas.13518
   PubMed Web of Science ®Google Scholar
• Hsu JM, Xia W, Hsu Y-H, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9(1):1908. doi:10.1038/s41467-018-04313-6
   PubMedGoogle Scholar
• Yamagata T, Tsuru T, Momoi MY, et al. Genome organization of human 48-kDa oligosaccharyltransferase (DDOST). Genomics. 1997;45(3):535–540. doi:10.1006/geno.1997.4966
   PubMed Web of Science ®Google Scholar
• Zhuang A, Yap FY, Bruce C, et al. Increased liver AGEs induce hepatic injury mediated through an OST48 pathway. Sci Rep. 2017;7(1):12292. doi:10.1038/s41598-017-12548-4
   PubMedGoogle Scholar
• Shapanis A, Lai C, Smith S, et al. Identification of proteins associated with development of metastasis from cutaneous squamous cell carcinomas (cSCCs) via proteomic analysis of primary cSCCs. Br J Dermatol. 2021;184(4):709–721. doi:10.1111/bjd.19485
   PubMed Web of Science ®Google Scholar
• Foulquier F, Amyere M, Jaeken J, et al. TMEM165 deficiency causes a congenital disorder of glycosylation. Am J Hum Genet. 2012;91(1):15–26. doi:10.1016/j.ajhg.2012.05.002
   PubMed Web of Science ®Google Scholar
• Stribny J, Thines L, Deschamps A, et al. The human Golgi protein TMEM165 transports calcium and manganese in yeast and bacterial cells. J Biol Chem. 2020;295(12):3865–3874. doi:10.1074/jbc.RA119.012249
   PubMed Web of Science ®Google Scholar
• Lee JS, Kim M-Y, Park E-R, et al. TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity. Oncol Rep. 2018;40(3):1297–1306. doi:10.3892/or.2018.6565
   PubMed Web of Science ®Google Scholar
• Wang Z, He L, Li W, et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer. 2021;9(9):e002787.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gao Y, Du C, et al. Hepatitis B-induced IL8 promotes hepatocellular carcinoma venous metastasis and intrahepatic treg accumulation. Cancer Res. 2021;81(9):2386–2398. doi:10.1158/0008-5472.CAN-20-3453
   PubMed Web of Science ®Google Scholar
• Gao Y, You M, Fu J, et al. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol. 2022;76(1):148–159. doi:10.1016/j.jhep.2021.08.029
   PubMed Web of Science ®Google Scholar